Desfibrilador automático en la miocardiopatía hipertrófica. Experiencia de 3 centros

Marín, Francisco; Gimeno, Juan R; Payá, Eduardo; García-Alberola, Arcadio; Pérez-Álvarez, Luisa; Fernández, Xusto; Morena, Gonzalo de la; Sogorb, Francisco; Castro-Beiras, Alfonso; Valdés, Mariano; Martínez, Juan G; Monserrat, Lorenzo.
Rev. esp. cardiol. (Ed. impr.) ; 59(6): 537-544, jun. 2006. tab
Artículo en Es | IBECS (España) | ID: ibc-048550

Documentos relacionados

  1. Genome Editing and Pathological Cardiac Hypertrophy.
  2. LncRNAs in cardiac hypertrophy: From basic science to clinical application.
  3. Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats.
  4. Myocardial protection of hypertrophied hearts by administration of cardioplegia according to regional myocardial temperature.
  5. Subcutaneous implantable cardioverter-defibrillator: Initial experience.
  6. Hepatocyte-Specific SR-BI Gene Transfer Corrects Cardiac Dysfunction in Scarb1-Deficient Mice and Improves Pressure Overload-Induced Cardiomyopathy.
  7. Engineered small extracellular vesicle-mediated NOX4 siRNA delivery for targeted therapy of cardiac hypertrophy.
  8. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets.
  9. [Effects of electroacupuncture at neiguan (PC6) on c-Jun NH2-teminal kinase signaling pathways in hypertrophic myocardial cells].
  10. Calpains and Coronary Vascular Disease.